Barclays lowered the firm’s price target on RadNet (RDNT) to $74 from $85 and keeps an Overweight rating on the shares. Against a backdrop of post-election volatility and downward estimate revisions, Barclays expects initial 2025 managed care guidance to “lean conservative and fall short of consensus expectations in many instances,” the analyst tells investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDNT:
- RadNet price target lowered to $80 from $100 at Jefferies
- RadNet price target raised to $100 from $82 at Jefferies
- RadNet price target raised to $85 from $79 at Barclays
- RadNet’s DeepHealth launches new AI-powered solutions at RSNA 2024
- RadNet’s DeepHealth expands FDA clearance for SmartMammo solution